Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Sells $8,838,570.00 in Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Director Roberto Mignone sold 519,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the completion of the transaction, the director now directly owns 981,000 shares of the company’s stock, valued at $16,706,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Teva Pharmaceutical Industries Trading Up 0.1 %

NYSE TEVA opened at $16.51 on Wednesday. The stock’s 50-day simple moving average is $15.79 and its two-hundred day simple moving average is $13.57. Teva Pharmaceutical Industries Limited has a twelve month low of $7.42 and a twelve month high of $17.69. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $18.69 billion, a price-to-earnings ratio of -40.26, a PEG ratio of 1.62 and a beta of 0.91.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.88% and a positive return on equity of 37.33%. The firm had revenue of $3.82 billion for the quarter, compared to analysts’ expectations of $3.70 billion. Research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its position in Teva Pharmaceutical Industries by 705.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company’s stock valued at $6,051,000 after purchasing an additional 507,568 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Teva Pharmaceutical Industries by 31.7% in the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after acquiring an additional 131,043 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Teva Pharmaceutical Industries by 42.2% during the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock valued at $3,515,000 after acquiring an additional 102,261 shares during the period. Gateway Investment Advisers LLC grew its position in Teva Pharmaceutical Industries by 28.6% during the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after acquiring an additional 9,312 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado increased its stake in Teva Pharmaceutical Industries by 1,382.8% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 255,826 shares of the company’s stock worth $2,671,000 after purchasing an additional 238,573 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TEVA. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Monday, May 20th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research note on Friday, March 8th. Barclays lifted their price objective on Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, June 5th. Piper Sandler reissued an “overweight” rating and set a $20.00 price objective (up previously from $19.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, May 13th. Finally, Bank of America lifted their price objective on Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, May 30th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.88.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.